Skip to content

OWP Pharmaceuticals Announces a Second IND Approval and Patent Application: The First-Ever Liquid Oral Suspension Formulation of Lamotrigine for the Treatment of Epilepsy and Bipolar Disorder

Share this press release:

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved.
Social Media Policy | Terms of Use

© 2022 OWP Pharmaceuticals, Inc., All Rights Reserved. Social Media Policy | Terms of Use